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Introduction: ADCY5 mutations have been recently identiﬁed as an important cause of early-onset hy-
perkinetic movement disorders. The phenotypic spectrum associated with mutations in this gene is
expanding. However, the ADCY5mutational frequency in cohorts of paediatric patients with hyperkinetic
movement disorders has not been evaluated.
Methods: We performed a screening of the entire ADCY5 coding sequence in 44 unrelated subjects with
genetically undiagnosed childhood-onset hyperkinetic movement disorders, featuring chorea alone or in
combination with myoclonus and dystonia. All patients had normal CSF analysis and brain imaging and
were regularly followed-up in tertiary centers for paediatric movement disorders.
Results: We identiﬁed ﬁve unrelated subjects with ADCY5 mutations (11% of the cohort). Three carried
the p. R418Wmutation, one the p. R418Q and one the p. R418G mutation. Mutations arose de novo in four
cases, while one patient inherited the mutation from his similarly affected father. All patients had
delayed motor and/or language milestones with or without axial hypotonia and showed generalized
chorea and dystonia, with prominent myoclonic jerks in one case. Episodic exacerbations of the baseline
movement disorder were observed in most cases, being the ﬁrst disease manifestation in two patients.
The disease course was variable, from stability to spontaneous improvement during adolescence.
Conclusion: Mutations in ADCY5 are responsible for a hyperkinetic movement disorder that can be
preceded by episodic attacks before the movement disorder becomes persistent and is frequentlyeuroscience, UCL Institute of Neurology, WC1N 3BG London, United Kingdom.
du (N.E. Mencacci).
ript.
ript.
r Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
M. Carecchio et al. / Parkinsonism and Related Disorders 41 (2017) 37e4338misdiagnosed as dyskinetic cerebral palsy. A residual degree of neck hypotonia and a myopathy-like
facial appearance are frequently observed in patients with ADCY5 mutations.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Adenyl cyclase 5, encoded by ADCY5, is a striatal-speciﬁc
enzyme that converts adenosine triphosphate (ATP) into cyclic
adenosine monophosphate (cAMP), an intracellular second
messenger crucial for several molecular pathways [1].
The role of pathogenic mutations in ADCY5 was ﬁrst recognized
in 2012, when a segregating missense change in the gene was
discovered in a large dominant kindred with multiple affected
members presenting with an early-onset hyperkinetic movement
disorder named Familial Dyskinesia with Facial Myokymia (FDFM;
OMIM 600293) [1,2]. A second de novo mutation (p.R418W) in
ADCY5 was subsequently found in two unrelated patients pre-
senting with childhood-onset chorea and dystonia [3] and
mutation-positive subjects were also found in a cohort of patients
with a clinical diagnosis of benign hereditary chorea (BHC) but no
NKX2-1 mutations [4]. The clinical phenotype associated with
ADCY5 mutations includes in most cases childhood-onset chorea
with episodic exacerbations observed more frequently upon
awakening, when falling asleep or during intercurrent illnesses
[5e8]. Besides chorea, various hyperkinetic movement disorders
such as myoclonus and dystonia have been described in ADCY5
positive subjects, but the prevalence of ADCY5 mutations in such
patients is unknown.
The aim of this study was to establish the contribution of ADCY5
mutations in a multi-centric cohort of patients with early-onset
hyperkinetic movement disorder who lacked a deﬁnite genetic
diagnosis.
We identiﬁed six new European cases with pathogenic ADCY5
mutations belonging to ﬁve different families, showing the clinical
course of disease at different ages, phenotypic heterogeneity and
variability of movement disorder.2. Materials and methods
In this study, we included patients displaying paediatric onset
hyperkinetic movement disorder featuring chorea alone or in
combination with myoclonus and dystonia, including patients
diagnosed with dyskinetic cerebral palsy (CP). Patients with sec-
ondary movement disorders, such as documented hypoxic injury at
birth or with detectable structural brain lesions were not included.
Patients enrolled had previously undergone extensive metabolic
screening (plasma and urinary aminoacids and organic acids,
lactate/pyruvate, cerebrospinal ﬂuid analysis including neuro-
transmitters and biopterins dosage) and multiple MRI brain scans
that were unrevealing. Mutations in the NKX2-1 gene, a signiﬁcant
though rare cause of childhood-onset chorea, were excluded in all
of these patients [9].
44 unrelated patients were included from ﬁve different Euro-
pean Centers (IRCCS C. Besta Neurological Institute, Milan; IRCCS
Santa Maria Nuova Hospital, Reggio Emilia; Movement Disorders
Department, HYGEIA Hospital, Athens; Second Department of
Neurology, Attikon Hospital, University of Athens; First Paediatric
Clinic, University of Athens, Agia Soﬁa Hospital, Athens). Details on
clinical history were obtained by direct interviewing the patients
and their relatives; in some cases, home-made videos were
retrieved and reviewed by the authors to better deﬁne the clinicalphenotype at earlier disease stages.
After obtaining informed consent (parental consent for minors
where applicable), patients were blood sampled and DNA was
extracted from peripheral blood lymphocytes according to stan-
dard procedures. ADCY5 exons 2 and 10, in which mutations have
been identiﬁed in most of the families published to date, were
Sanger sequenced. Samples without mutations in these two exons
were submitted for Whole Exome Sequencing (WES), which was
performed as previously reported [10]. Segregation analysis in
available family members was performed in all positive cases.3. Results
Five out of 44 unrelated patients (11%) carried ADCY5mutations.
Four patients were sporadic and carried de novo changes, while one
had an autosomal dominant family history and inherited the mu-
tation from his 47-year-old father, who also suffered from
childhood-onset generalized chorea and dystonia. All mutations
detected were located in ADCY5 exon 2, at amino acidic residue 418
(p.R418W in 3 patients, p. R418G and p. R418Q in one each).
Analysis of WES data did not reveal any additional mutation in
ADCY5 located outside exons 2 and 10 in the remainder 39 patients.
Clinical features of positive patients are summarized in Table 1.
Patient 1 (p.R418W; de novomutation) is a 15-year-old girl born
pre-term from healthy parents. She presented with axial hypotonia
(Video 1 - Segment 1) and delayed language. Around 11 months
she developed abrupt brief generalized dystonic attacks when
falling asleep. Between age 1 and 2, generalized chorea also
appeared during attacks, that occurred in clusters on a weekly
basis. Around 18 months of age she developed generalized chorea
with a slowly progressive course until age 13 (Video 1 - Segment
2), and subsequent spontaneous improvement; at age 9 she
developed left foot dystonia (in-turning). Due to chorea and severe
axial hypotonia she could walk independently only at age 5; re-
sidual neck hypotonia is still present to date. Routine EEG and sleep
studies did not show cortical correlates of movement disorder and
brain MRI was unremarkable. She initially received a diagnosis of
dyskinetic CP. On examination at age 15 (Video 1e Segment 3), her
mouth was slightly open, she showed generalized chorea involving
also perioral muscles, dystonic posturing of upper and lower limbs,
head drop and severe dysarthria with saliva drooling. Her total IQ
(84) was in the borderline range (WISC). During teen age, episodic
exacerbations of chorea and dystonia during sleep became shorter
and less frequent and are now present about once a month.
Episodic exacerbations also occur during the day with two distinct
patterns: 1) sudden give-way of legs with falls to the ground with
preserved consciousness and 2) generalized dystonic-choreic at-
tacks favored by tiredness and narrow passages. Trihexyphenidyl
up to 32 mg/day did not improve signiﬁcantly motor symptoms.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2017.05.004.
Patient 2 (p.R418Q; de novo mutation) is an Italian 18-year-old
boy born from healthy parents. He presented with delayed motor
milestones and a tendency to tiptoe walking at 18 months. Since 6
months of age, nocturnal attacks of generalized dystonia with
inconsolable crying, lasting up to some hours, disrupted his sleep.
During infancy he developed generalized chorea and mild
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M. Carecchio et al. / Parkinsonism and Related Disorders 41 (2017) 37e43 39myoclonic jerks also involving facial muscles (Video 2 e Segment
1) and he showed a mildly scissoring gait with pyramidal signs in
the lower limbs, for which he underwent tendon elongation.
Episodic worsening of dyskinesias accompanied by hyperventila-
tion, lasting about half an hour, were noticed during childhood,
triggered by emotions and stress; sometimes hyperventilation and
tachypnoea occurred without exacerbation of dyskinesias. These
episodes initially recurred at weekly intervals and then spontane-
ously decreased over disease course. Currently, diurnal and
nocturnal exacerbations are almost abolished (about one episode a
year is reported), the most recent one being triggered by a minor
orthopedic injury. Chorea slowly improved during teen-age years,
and the clinical picture became dominated by dystonia and
myoclonus. On examination at age 17, he showed mildly scissoring
gait with pyramidal signs in the lower limbs, mild dysarthria with a
tendency to keep his mouth open, cervical dystonia, multifocal
non-stimulus sensitive myoclonic jerks at rest and on posture more
prominent in the upper body, also involving the perioral muscles
(Video 2 - Segment 2). Standard EEG and sleep studies showed no
EEG correlates of hyperkinesias. EMG recordings revealed bursts of
100e120 ms in the upper limbs and neck, alone or superimposed
on dystonic co-contraction of antagonistic muscle groups, consis-
tent with the co-occurrence of myoclonus and dystonia, as
observed in DYT11 positive patients [11]. Clonazepam was not
beneﬁcial in reducing myoclonus. The patient's IQ (WISC) at age 7
was 86.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2017.05.004.
Patient 3 (p.R418G; inherited mutation) is a 3-year-old Italian
boy born full-term after normal pregnancy. Motor and language
development were delayed, he managed to sit unsupported at 17
months and towalk unassisted at 2 years of age. Generalized chorea
appeared in the ﬁrst months of life. Neurological examination at
age 2.5 showed axial hypotonia, mild generalized chorea and dys-
tonic posturing of the limbs (tiptoe walking). To date, the patient
has not presented diurnal or nocturnal paroxysmal exacerbations
of chorea. His father (Patient 4), 47 years old, had delayed motor
and language milestones. Generalized chorea with dystonic
posturing of upper limbs appeared around age 3. Since childhood,
he has suffered from severe and painful exacerbations of dyskine-
sias triggered by emotions and tiredness and also present during
sleep. Chorea is currently worsened by action, emotions and stress
(Video 3). Acetazolamide signiﬁcantly improved its severity,
whereas tetrabenazine, baclofen and trihexyphenidyl were not
effective. His son was started on acetazolamide (125 mg/day) with
no substantial changes in his mild movement disorder.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2017.05.004.
Both the patient and his father carried the p. R418G change;
visual inspection of the chromatograms showed an imbalanced
ratio between the wild-type and the mutated allele, with the latter
signiﬁcantly less represented (Fig. 1). This was not observed in the
son, suggesting that the father could be a mosaic for the mutation.
Patient 5 (p.R418W; de novomutation) is a 35-year-old woman
of Greek origin, born full term after an uneventful pregnancy. At 3
months of age she had failure to thrive, feeding difﬁculties, and
developed choreic movements. At the age of 9 months she could
not sit unsupported and showed axial hypotonia. At age two, she
had a mild cognitive and motor developmental delay. She initially
received a diagnosis of dyskinetic CP, with normal intelligence. Her
clinical picture remained stable until age 7, when she developed
sudden attacks characterized by hip and trunk ﬂexion that made
her collapse to the ground with no alteration of consciousness
(Video 4 e Segment 1). She also developed sustained dystonic
postures of the limbs both throughout the day and night,
Fig. 1. Pedigree of patients 3 and 4. The electropherogram of Patient 4 (II.1) shows an unbalanced ratio between the wild-type and the mutant allele (top panel), with the wild-type
signiﬁcantly more represented, suggesting somatic mosaicism. This was not observed in Patient 3 (III.2), where the chromatograms of the normal and mutated allele are equiv-
alently represented (bottom panel).
M. Carecchio et al. / Parkinsonism and Related Disorders 41 (2017) 37e4340particularly upon awakening, which at times were extremely
painful. Multiple brain MRI scans and EEGs were normal. Over the
following years, chorea remained stable and the paroxysmal epi-
sodes had a variable course, with spontaneous remission for about
two years and reappearance at age 23 after a traumatic event. The
episodes lasted up to 30 min and could occur many times a day and
were diagnosed as functional (psychogenic). On examination at age
35 (Video 4 e Segment 2), her mouth was slightly open and she
had some drooling, and a dysarthric speech. Chorea was present in
the face, involving mainly the mouth, and limbs were mildly
affected as well, especially the arms. There was dystonic posturing
of the feet and hands when outstretched. She was hypotonic, re-
ﬂexes were present and symmetric throughout. Sleep studies
showed hypoventilation triggering paroxysmal episodes at night,
for which she was given a CPAP treatment with some improvement
of the nocturnal episodes. Tetrabenazine, levodopa, trihex-
yphenidyl, various anticonvulsants were not helpful. Clonazepam
signiﬁcantly improved the frequency and severity of the parox-
ysmal episodes. The patient was found to carry a de novo p. R418W
mutation.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.parkreldis.2017.05.004.
Patient 6 (p.R418W; de novo mutation) is a 5 year-old Greek
child born full term from healthy parents. He had delayed mile-
stones and generalized hypotonia and was able to sit unassisted
and to stand with support only at 20 months of age. He also had
delayed language development, though verbal understanding was
good. Generalized chorea appeared around age one, and about one
year later he developed brief diurnal paroxysmal events lasting less
than one minute, that were characterized by limb posturing, more
severe in the arms, associated with possible axial posturing. Brain
MRI and CSF analysis were unremarkable. On examination at age 5,
he was able to follow simple commands and had moderate
generalized chorea involving also the face, along with generalized
hypotonia. Paroxysmal dystonic attacks are still present, especially
upon awakening. A trial of Levodopa was not effective and no
additional medication was started.4. Discussion
Since the original report in 2001 [2], in which the authors
described the movement disorder in the affected family members
as “Familial Dyskinesia with Facial Myokymia”, the phenotypic
spectrum associated with ADCY5 mutations has expanded and a
more detailed delineation of movement disorders has been pro-
vided in subsequent reports [3e5,7].
So far, 60 genetically conﬁrmed patients (24 sporadic, 36 familial
cases) belonging to 36 different families have been reported
(Table 2). The mutational frequency of ADCY5 in homogeneous
cohorts of patients with early-onset non-progressive hyperkinetic
movement disorders has not been assessed in previous publica-
tions, and some authors identiﬁed positive subjects in extensive
screenings of patients affected by heterogeneous movement dis-
orders [12]. In this study, we aimed at deﬁning the contribution of
ADCY5 mutations in a cohort of patients with a childhood-onset
hyperkinetic movement disorder. We found that 11% of our
cohort carried ADCY5 pathogenic mutations. These patients dis-
played most of the previously described features of ADCY5-associ-
ated disease: (a) onset in infancy-childhood with delayed
milestones and axial hypotonia, (b) a mixed hyperkinetic move-
ment disorder mostly characterized by generalized chorea and
dystonia and (c) frequent exacerbations of dyskinesias upon
awakening and when falling asleep. Importantly, differently from
subjects with ADCY5 mutations, these core features were not
observed all together in any of the 39 subjects without mutations,
suggesting that their concomitant presence is a strong predictor of
the mutational status.
Some patients were previously diagnosed with dyskinetic CP
despite normal MRI ﬁndings and no clear perinatal injury. While
movement disorders in CP can show signiﬁcant worsening during
intercurrent infections, a clear relationship between the exacer-
bations of movement disorders and sleep should raise the suspicion
of a misdiagnosis and lead to consider underlying ADCY5
mutations.
Chorea presenting in infancy is often due to acute basal ganglia
Table 2
ADCY5 positive patients and kindred reported in the literature to date.
Publication ADCY5 positive patients Affected subjects reporteda No of kindred ADCY5 mutation (no of kindred, no of positive patients)
Chen et al., 2012 [1] 10 18 1 p.A726T
Chen et al., 2014 [3] 2 2 2 p.R418W
Chen et al., 2015 [5] 24 30 15 p.R418W (8 K, 9)
p.R418Q (3 K, 3)
p.A726T (1 K, 6)
p.L720P (1 K, 1)
p.R438P (1 K, 1)
p.M1029K (1K, 4)
Mencacci et al., 2015 [4] 3 3 2 p.R418W
Carapito et al., 2015 [6] 2 2 1 c.2088þ1G > A
Chang et al., 2016 [7] 6 10 6 p.R418W (4 K, 4)
p.R418G (1 K, 1)
p.R418Q (1 K, 1)
Dy et al., 2016 [8] 3 4 3 p.R418W (2 K, 2)
p.K694_M696 (1 K, 1)
Zech et al., 2016 [12] 3 3 2 p.I460F (1K, 1)
p.R727K (1K, 2)
Meijer et al., 2016 [15] 1 1 1 p.R418W
Westenberger et al., 2016 [17] 2 2 2 p.D1015E (1K, 1)
p.E1025V (1K, 1)
Douglas et al., 2017 [18] 4 5 1 p. M1029R
TOTAL 60 80 36
K: kindred.
a Including clinically affected subjects lacking genetic conﬁrmation.
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acidopathies, organic acidurias, Lesh-Nyhan syndrome), while in
childhood auto-immune causes with normal brain imaging prevail
(Sydenham's chorea, autoimmune encephalitides) and rare non-
metabolic genetic conditions must also be considered (NKX2-1,
PDE10A, GNAO1 mutations) [13].
Age at onset of paroxysmal dyskinesias and dystonia ranged
between 6 months and seven years of age in our study, being the
ﬁrst disease manifestation (along with delayed milestones) in one
third of positive patients, and developing before a chronic move-
ment disorder became evident. Onset in the ﬁrst months of life and
relation to sleep is unusual in paroxysmal movement disorders due
to PRRT2, PNKD and SLC2A1 mutations, thus mutations in ADCY5
should be considered in the differential of paroxysmal movement
disorders with a very early onset even in the absence of a detectable
chronic movement disorder. On the other hand, as exempliﬁed by
Patient 3, who displays mild chorea and dystonia without parox-
ysmal exacerbations, the absence of suchmanifestations, suggested
as a “red ﬂag” for ADCY5-related dyskinesias [14], does not rule
ADCY5 mutations out, at least in the ﬁrst years of life.
The natural history of ADCY5-related dyskinesias is still poorly
deﬁned and no or little progression of movement disorder has been
observed in previous reports. Phenotypic variability has been partly
attributed to genotype-phenotype correlation, with available evi-
dence suggesting that the A726T mutation is associated with a
milder phenotype [5], whereas the p. R418W is responsible for a
more severe clinical picture. A lesser degree of severity of move-
ment disorder has also been explained with somatic mosaicism
[4,5]. In our series, chromatograms of Patient 4 (Fig. 1) were sug-
gestive of somatic mosaicism; however, he displayed a relatively
severe phenotype as compared to his son. This might indicate that
additional genetic and/or environmental factors may play a role in
determining ADCY5 phenotypic variability.
In our series, patients were regularly assessed for several years,
thus disease course and phenomenology could be documented at
different ages. All patients presented with delayed ability to sit
unsupported or walk independently and showed a combination of
axial hypotonia and chorea/dystonia affecting also the lower limbs
together with spasticity in one case (Patient 2). Axial hypotoniaslowly improved over disease course, but a residual degree of cer-
vical hypotonia could still be observed in adolescence in some
affected subjects (Patient 1 and 2). Cervical hypotonia in adoles-
cents and young adults can mimic dystonic anterocollis, and it is
detectable in other positive patients from previously published
videos [7], thus representing a potential additional clue to indi-
viduate ADCY5 mutation carriers, as observed by Meijer et al. [15].
Abrupt violent head drops are considered characteristic of chorea-
acanthocytosis [16], but are phenomenologically different from
what has been observed in ADCY5 cases.
The course of dyskinesia exacerbations was variable in our se-
ries, including spontaneous amelioration in frequency and severity
(Patient 1), almost complete remission during teen age (Patient 2),
stability since onset (Patient 4 and 6) and stability with relatively
long attack-free periods (Patient 5). Peripheral traumawas reported
in two cases to trigger recrudescence of attacks after free periods.
Movement disorder disease course was variable as well, with
spontaneous improvement of chorea observed in some cases dur-
ing adolescence and relative stability since childhood in others.
Patient 2 switched from a choreic/dystonic phenotype in
childhood to a clinical and electrophysiological picture consistent
with myoclonus-dystonia in his late teens, and was in fact previ-
ously tested for DYT11 mutations; however, the presence of pyra-
midal signs in the lower limbs and delayed milestones in infancy
were not consistent with the classic myoclonus-dystonia pheno-
type due to DYT11 mutations.
In terms of treatment, several agents such as tetrabenazine,
trihexyphenidyl, levodopa and anticonvulsant were not beneﬁcial.
Of note, acetazolamide, a carbonic anhydrase inhibitor, signiﬁcantly
improved chorea in Patient 4; response of dyskinesia to this drug,
though considered nonspeciﬁc, was reported in two patients of the
original family published by Fernandez et al. [2]. Clonazepam
reduced the dystonic episodes in Patient 5 but was ineffective in
ameliorating myoclonus in Patient 2. Given the unsatisfactory
response of ADCY5-related movement disorders to several drugs,
bilateral GPi Deep Brain Stimulation (DBS) has been recently per-
formed in four patients, with moderate reduction of hyperkinetic
movements [8,15].
In our series, all positive patients carried mutations involving
Table 3
Frequency of ADCY5 mutations reported.
ADCY5 mutation Affected cases reported (%)a Number of kindred reported (%)a
c.1252C > T; p.R418W 24 (36,4%) 22 (54%)
c.2176G > A; p.A726T 16 (24,2%) 2 (4,9%)
c.1253G > A; p.R418Q 5 (7,6%) 5 (12.2%)
c.3086T > A; p.M1029K 4 (6%) 1 (2,4%)
c.3086T > G; p. M1029R 4 (6%) 1 (2,4%)
c.1252C > G; p.R418G 3 (4,5%) 2 (4,9%)
c.2088þ1G > A 2 (3%) 1 (2,4%)
c.2180G > A; p.R727K 2 (3%) 1 (2,4%)
c.2159T > C; p.L720P 1 (1,5%) 1 (2,4%)
c.1313G > C; p.R438P 1 (1,5%) 1 (2,4%)
c.2080_2088del; p.K694_M696 1 (1,5%) 1 (2,4%)
c.3045C > A; p.D1015E 1 (1,5%) 1 (2,4%)
c.3074A > T; p.E1025V 1 (1,5%) 1 (2,4%)
c.1378A > T; p.I460F 1 (1,5%) 1 (2,4%)
Total 66 (100%) 41 (100%)
a Including the present paper.
M. Carecchio et al. / Parkinsonism and Related Disorders 41 (2017) 37e4342the arginine 418, and half of them carried the p. R418W mutation,
which is by far the most frequently encountered missense variant,
being present in 19/36 (53%) unrelated probands reported to date.
With our series, the total number of ADCY5 positive patients rea-
ches 66 cases and the number of unrelated patients carrying the p.
R418W mutation increases up to 22/41 (54%) (Table 3). We there-
fore conﬁrm that arginine 418 is a mutational hot spot in ADCY5
with a relevant pathogenic role.
5. Conclusions
Mutations in ADCY5 represent a signiﬁcant genetic cause of
early-onset non-progressive hyperkinetic movement disorders,
with a frequency of 11% in our series. The increasing number of
cases reported is contributing to deﬁne the phenotypic spectrum of
this disorder. Delayed milestones and axial hypotonia seem to be
almost universal features in infancy, while onset of movement
disorder and its episodic or chronic nature are variable in the ﬁrst
disease phases and tend sometimes to spontaneously improve with
age. We suggest testing for ADCY5 mutations patients previously
diagnosed with dyskinetic cerebral palsy when exacerbations of
dyskinesia are clearly sleep-related. The knowledge about long-
term motor outcome in affected children is still limited, given the
relatively small number of cases reported so far. We observed some
common features in most patients, including the presence of “head
drop” probably due to residual cervical hypotonia as well as a
myopathy-like appearance of face with mouth kept slightly open.
These characteristics may be relevant in patients without frequent
episodic movement disorder exacerbations and suggest underlying
ADCY5 mutations, although their pathophysiology still needs to be
elucidated.
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